Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]AlF-RESCA-IL2
- Development stage
- Unknown
- Lead developer
- University Medical Center Groningen
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
[18F]AlF-RESCA-IL2 is a radiopharmaceutical positron emission tomography (PET) imaging agent designed to non-invasively visualize and quantify the presence of activated T-lymphocytes within the body. It consists of the cytokine Interleukin-2 (IL-2) conjugated to an aluminum fluoride-18 ([18F]AlF) complex via a restrained complexing agent (RESCA). The tracer specifically targets the Interleukin-2 receptor alpha subunit (IL-2Rα), also known as CD25, which is highly upregulated on the surface of activated T-cells. Developed primarily to monitor the immune landscape in the tumor microenvironment, [18F]AlF-RESCA-IL2 allows clinicians to assess the infiltration and activation of tumor-infiltrating lymphocytes (TILs) in patients undergoing cancer immunotherapy, such as immune checkpoint inhibition. This functional imaging approach aims to provide a predictive biomarker for treatment response and to help distinguish between pseudo-progression and true tumor growth.
- Other names
- 18F-labeled AlF-RESCA-interleukin-2Fluorine-18 AlF-RESCA-IL2Fluorine18 AlF-RESCA-IL2Fluorine 18 AlF-RESCA-IL2
02
Targets
IL2RB (IL-2 receptor beta chain)
Beyond the preview
Go deeper on [18F]AlF-RESCA-IL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [18F]AlF-RESCA-IL2.